Navigation Links
Aflibercept in AMD: No proof of added benefit
Date:6/5/2013

The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any suitable data for this comparison.

Patients in control group did not receive approval-compliant treatment

The Federal Joint Committee (G-BA) specified the drug ranibizumab as appropriate comparator therapy. In its dossier the pharmaceutical company cited two approval studies of aflibercept that directly compared aflibercept with ranibizumab. But in these studies, ranibizumab was not used according to its approval status. For instance, the continuation or discontinuation of treatment was not made dependent on whether the patients had achieved stable visual acuity or not. Although the manufacturer cited other documents in its dossier, these cannot be used for the benefit assessment, as they do not allow any reliable conclusions to be drawn on the comparison of aflibercept and ranibizumab. Overall, no added benefit of aflibercept can be derived from the data presented in the dossier.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1

Related medicine news :

1. No Proof That Gum Disease Causes Heart Disease, Experts Say
2. More Proof That Healthy Habits Fight Disease
3. More Proof Cranberry Juice Thwarts Infection
4. No proof that patients lose weight after joint replacement surgery
5. Vandetanib in thyroid cancer: No proof of added benefit
6. No Proof That Doping With EPO Gives Athletes an Edge: Review
7. Corporate Whistle Blower Center Now Urges Physicians, Medical Device or Drug Insiders With Proof A Company Knowingly Sold A Bad Product to Become a Whistleblower
8. Corporate Whistle Blower Center Now Urges Physicians to Become a Whistleblower if They Have Proof a Medical Device or a Drug Product was Defective-and it was Sold Anyway
9. Pesticides and Parkinsons: UCLA researchers uncover further proof of a link
10. Corporate Whistle Blower Center Now Urges Physicians Medical Device and Drug Industry Insiders To Step Up-If They Have Proof Of Serious Wrongdoing or Overbilling
11. No Proof Drugs Ease Kids Migraines: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Park, KS (PRWEB) , ... January 18, 2017 ... ... managed firm offering asset protection and financial planning services to families and business ... a charity event aimed at supporting children with developmental disabilities. , The Lakemary ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the ... project with the donation of cochlear implants. In February 2017, the first three ... a fair chance of leading an independent life. This engagement builds on the ...
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... , The company, owned and operated by Ed Stroup, was created to ... price with the highest level of customer service. Healthful Balance products can be ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 EU5 Glucose Monitoring Market ... report, "EU5 Glucose Monitoring Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segments - Blood Glucose Meters, Blood Glucose Test Strips ... and distribution shares data for each of these market ...
(Date:1/17/2017)... 17, 2017 The interventional radiology products market ... from USD 6.35 billion in 2016, at a CAGR ... of this market are rising incidence of chronic diseases, ... surgeries. The global interventional radiology products market ... On the basis of type, the stents segment is ...
(Date:1/17/2017)... -- The Global Nebulizers Market is poised to grow ... decade to reach approximately $1698.68 million by 2025. Some ... include rapidly growing demand in emerging regions, increasing use ... and online marketing strategies by key players. ... pneumatic nebulizers, ultrasonic nebulizers and mesh nebulizers. Pneumatic nebulizers ...
Breaking Medicine Technology: